| Literature DB >> 19540544 |
Niroshan Thanthrige-Don1, Mohamed F Abdul-Careem, L Allen Shack, Shane C Burgess, Shayan Sharif.
Abstract
Marek's disease virus (MDV), which causes a lymphoproliferative disease in chickens, is known to induce host responses leading to protection against disease in a manner dependent on genetic background of chickens and virulence of the virus. In the present study, changes in the spleen proteome at 7, 14 and 21 days post-infection in response to MDV infection were studied using two-dimensional polyacrylamide gel electrophoresis. Differentially expressed proteins were identified using one-dimensional liquid chromatography electrospray ionization tandem mass spectrometry (1D LC ESI MS/MS). Comparative analysis of multiple gels revealed that the majority of changes had occurred at early stages of the disease. In total, 61 protein spots representing 48 host proteins were detected as either quantitatively (false discovery rate (FDR)<or=0.05 and fold change>or=2) or qualitatively differentially expressed at least once during different sampling points. Overall, the proteins identified in the present study are involved in a variety of cellular processes such as the antigen processing and presentation, ubiquitin-proteasome protein degradation (UPP), formation of the cytoskeleton, cellular metabolism, signal transduction and regulation of translation. Notably, early stages of the disease were characterized by changes in the UPP, and antigen presentation. Furthermore, changes indicative of active cell proliferation as well as apoptosis together with significant changes in cytoskeletal components that were observed throughout the experimental period suggested the complexity of the pathogenesis. The present findings provide a basis for further studies aimed at elucidation of the role of these proteins in MDV interactions with its host.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19540544 PMCID: PMC7103390 DOI: 10.1016/j.virol.2009.05.020
Source DB: PubMed Journal: Virology ISSN: 0042-6822 Impact factor: 3.616
Fig. 1Representative 2D gel images of MDV-infected and uninfected control spleen proteomes with their respective sampling points. Arrows with accompanying spot numbers show successfully identified protein spots that were uniquely expressed (qualitative differences) in each group at corresponding time point. Please refer to Table 1 for identities of corresponding spot numbers and to Fig. 2 for the map of quantitatively differentially expressed spots.
Fig. 2A representative gel image showing 2D gel electrophoresis map of the relative locations of spots that displayed significant quantitative differential expression (FDR ≤ 0.05 and fold change ≥ 2) at least once during different sampling times. This image represents the proteome of 7 dpi MDV-infected spleen. Because of the absence of certain spots in this gel, arrows for spot 111, 968, 1576 and 1609 represent the relative positions only. Please refer to Table 1 for identities of corresponding spot numbers and to Fig. 1 for maps of qualitatively differentially expressed spots.
Fig. 3Comparison of total numbers of significantly differentially expressed protein spots in MDV-infected spleens at various sampling time points. In calculation of total number of spots in each category, newly induced protein spots were considered as up-regulation and the absence of spots compared to uninfected controls was considered as down-regulation.
List of differentially expressed protein spots in MDV-infected spleen tissues identified by 1D LC ESI MS/MS.
| Ref. spot no. | Protein name | Fold change in expression | Number of peptides identified | Protein coverage | Probability | Protein score | Accession no. | Mr. (predicted/observed) (kDa) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 7 dpi | 14 dpi | 21 dpi | ||||||||
| 1738 | PREDICTED: similar to Coactosin-like 1 ( | IN | 1.6 | REP | 1 | 17 | 5.3E− 12 | 5.62 | gi|118096533 | 15.9/15.34 |
| 628 | Beta-actin (ACTB) | 4.2 | 1 | 1.1 | 3 | 12 | 5.0E− 40 | 28.36 | gi|45382927 | 41.7/34.23 |
| 1614 | Beta-actin (ACTB) | IN | IN | AB | 1 | 3 | 0.00028 | 2.95 | gi|45382927 | 41.7/37.84 |
| 1616 | Beta-actin (ACTB) | IN | 4.9 | IN | 4 | 28 | 7.8E− 69 | 38.18 | gi|45382927 | 41.7/36.15 |
| 1757 | Beta-actin (ACTB) | IN | IN | AB | 2 | 9 | 1.2E− 28 | 16.17 | gi|45382927 | 41.7/34.20 |
| 1567 | Beta-actin (ACTB) | 2.5 | 2 | 1.8 | 4 | 19 | 6.2E− 55 | 41.75 | gi|45382927 | 41.7/36.54 |
| 1615 | Actin, alpha 2, smooth muscle, aorta (ACTA2) | IN | AB | REP | 2 | 8 | 1.4E− 12 | 5.93 | gi|71895043 | 42.0/36.90 |
| 762 | Actin, alpha 2, smooth muscle, aorta (ACTA2) | 4.2 | 1.8 | 1.3 | 4 | 11 | 1.8E− 38 | 26.37 | gi|71895043 | 42.0/28.52 |
| 709 | Actin, alpha 2, smooth muscle, aorta (ACTA2) | 2.7 | 2.5 | 1 | 3 | 8 | 1.1E− 32 | 20.67 | gi|71895043 | 42.0/30.65 |
| 325 | Tubulin, beta 2B (TUBB2B) | − 3.3 | − 1.1 | 1.6 | 12 | 63 | 2.0E− 139 | 106.89 | gi|52138699 | 49.9/56.70 |
| 1755 | Lamin B2 (LMNB2) | IN | IN | IN | 8 | 24 | 4.3E− 54 | 45.33 | gi|45384202 | 67.9/40.33 |
| 1426 | Lamin B2 (LMNB2) | 3.1 | IN | 1.3 | 7 | 19 | 4.7E− 60 | 48.54 | gi|45384202 | 67.9/40.65 |
| 1763 | Eukaryotic translation elongation factor 2 (EEF2) | IN | IN | 1.9 | 9 | 23 | 9.9E− 81 | 46.07 | gi|45382453 | 95.4/33.69 |
| 612 | Eukaryotic translation elongation factor 2 (EEF2) | 3.2 | 1.1 | 1.5 | 8 | 19 | 4.3E− 93 | 57.94 | gi|45382453 | 95.4/34.01 |
| 1782 | Acidic ribosomal phosphoprotein (RPLP0) | REP | 1 | AB | 6 | 31 | 7.6E− 56 | 39.02 | gi|45384494 | 34.3/36.14 |
| 1626 | Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) | IN | IN | AB | 1 | 4 | 5.9E− 10 | 7.72 | gi|71896753 | 36.8/23.05 |
| 1631 | PREDICTED: heterogeneous nuclear ribonucleoprotein A3 (HNRNPA3) | 3.6 | 2.3 | − 1.8 | 3 | 17 | 1.1E− 19 | 9.52 | gi|118093536 | 39.6/29.05 |
| 541 | Heterogeneous nuclear ribonucleoprotein H3 (2H9) (HNRNPH3) | − 3.7 | − 1.4 | 1.3 | 7 | 38 | 8.9E− 69 | 45.22 | gi|60302824 | 36.5/36.50 |
| 769 | Ubiquitin carboxyl-terminal esterase L3 (UCHL3) | − 2.5 | − 1.5 | − 1.4 | 2 | 14 | 4.9E− 17 | 14.20 | gi|45382251 | 26.3/28.34 |
| 710 | Proteasome (prosome, macropain) subunit, beta type, 7 (PSMB7) | REP | − 1.3 | 1.1 | 2 | 13 | 2.1E− 15 | 12.47 | gi|45383366 | 29.9/30.78 |
| 1576 | PREDICTED: similar to mSUG1 protein (PSMC5) | REP | AB | 2.6 | 2 | 19 | 3.3E− 24 | 13.53 | gi|118102836 | 45.6/47.87 |
| 1171 | Cathepsin D (CathD) | 2.8 | 2 | 2.5 | 2 | 13 | 1.0E− 14 | 8.96 | gi|45384002 | 43.3/13.30 |
| 1747 | Cathepsin D (CathD) | 2 | 2.5 | 1.8 | 1 | 7 | 2.8E− 10 | 6.57 | gi|45384002 | 43.3/28.46 |
| 494 | Cathepsin D (CathD) | REP | − 1.2 | − 1.9 | 1 | 7 | 1.8E− 10 | 5.32 | gi|45384002 | 43.3/39.21 |
| 1569 | MHC class II alpha chain (B-LA) | − 3.6 | 1 | − 1.3 | 1 | 14 | 0.00099 | 3.33 | gi|118099043 | 28.0/32.14 |
| 1609 | PREDICTED: similar to D4-GDP-dissociation inhibitor (D4-GDI) | 5.3 | 1.6 | − 1.3 | 1 | 4 | 0.00745 | 2.26 | gi|50728568 | 23.0/18.40 |
| 775 | PREDICTED: similar to D4-GDP-dissociation inhibitor (D4-GDI) | − 2.7 | − 2.5 | − 1.6 | 5 | 49 | 2.3E− 77 | 51.21 | gi|50728568 | 23.0/27.15 |
| 1174 | Membrane associated guanylate kinase, WW and PDZ domain containing (MAGI3) | 6.3 | 2.7 | 3.4 | 1 | 3 | 0.00043 | 2.40 | gi|60593020 | 12.2/13.70 |
| 583 | Guanine nucleotide binding protein (G protein), beta polypeptide 1 (GNB1) | − 2 | − 1.2 | − 1.2 | 1 | 8 | 6.3E− 21 | 9.42 | gi|61098210 | 37.3/35.15 |
| 1125 | Transthyretin (TTR) | REP | − 1.1 | REP | 1 | 11 | 4.0E− 05 | 2.96 | gi|45384444 | 16.3/15.28 |
| 1607 | Alpha 2 globin (HBA2) | 2.8 | 1 | − 1.3 | 9 | 85 | 1.9E− 95 | 76.78 | gi|52138645 | 15.7/27.34 |
| 1155 | Fatty acid binding protein 4, adipocyte (FABP4) | REP | AB | AB | 5 | 56 | 4.7E− 46 | 29.37 | gi|45383556 | 14.8/14.55 |
| 1143 | Fatty acid binding protein 3 (FABP3) | 1.2 | IN | IN | 3 | 80 | 4.2E− 87 | 50.64 | gi|71894843 | 14.8/14.80 |
| 1605 | PREDICTED: similar to voltage-gated sodium channel type II alpha subunit (SCN2A) | IN | AB | AB | 1 | 2 | 0.00661 | 3.15 | gi|118093616 | 25.5/32.35 |
| 598 | Proliferating cell nuclear antigen (PCNA) | − 1.6 | 1.4 | 2.7 | 6 | 46 | 3.1E− 45 | 29.16 | gi|45383776 | 28.9/34.36 |
| 1781 | Nucleophosmin 1 (NPM1) | 3.2 | 1.1 | 1.5 | 1 | 6 | 1.1E− 14 | 8.85 | gi|45383996 | 32.6/20.09 |
| 1040 | Stathmin 1/oncoprotein 18 (STMN1) | REP | 1 | IN | 1 | 13 | 1.0E− 09 | 5.36 | gi|50053682 | 17.1/18.67 |
| 1769 | Triosephosphate isomerase 1 (TPI1) | IN | AB | AB | 2 | 13 | 5.0E− 08 | 5.76 | gi|45382061 | 26.6/27.19 |
| 789 | Triosephosphate isomerase 1 (TPI1) | − 2.3 | − 1.5 | − 1.4 | 3 | 18 | 4.5E− 25 | 22.54 | gi|45382061 | 26.6/27.26 |
| 1604 | PREDICTED: aldolase B, fructose-bisphosphate (ALDOB) | 5.2 | 2.7 | 2.6 | 1 | 2 | 1.9E− 05 | 4.90 | gi|50761947 | 39.3/38.76 |
| 1629 | PREDICTED: aldolase B, fructose-bisphosphate (ALDOB) | − 5.4 | − 1.6 | 1 | 1 | 2 | 0.00261 | 2.48 | gi|50761947 | 39.3/39.68 |
| 791 | Glutathione-S-transferase theta 1 (GSTT1) | − 1.4 | REP | 1 | 1 | 13 | 0.00015 | 2.41 | gi|45382479 | 29.8/27.14 |
| 1596 | Phosphoglycerate mutase 1 (brain) (PGAM1) | − 4.9 | 1 | IN | 10 | 83 | 4.1E− 169 | 95.00 | gi|71895985 | 28.9/29.17 |
| 283 | Amylase, alpha 2A; pancreatic (AMY2A) | − 3.5 | − 1.3 | − 5.7 | 13 | 72 | 3.9E− 180 | 120.50 | gi|47825395 | 57.5/58.61 |
| 1702 | Heat shock cognate 70 (HSC70) | IN | AB | AB | 9 | 31 | 2.3E− 141 | 87.04 | gi|45384370 | 70.8/66.08 |
| 1603 | Heat shock protein 70 (HSP70) | IN | AB | REP | 2 | 6 | 1.5E− 27 | 16.43 | gi|55742654 | 69.7/40.14 |
| 1735 | Heat shock protein 70 (HSP70) | IN | REP | REP | 3 | 10 | 6.7E− 25 | 18.12 | gi|55742654 | 69.7/69.27 |
| 1527 | PREDICTED: similar to natural killer cell enhancing factor isoform 4 (NKEF) | 6.3 | 2 | 1.2 | 7 | 49 | 5.1E− 78 | 60.88 | gi|50751518 | 22.1/24.61 |
| 1606 | PREDICTED: similar to natural killer cell enhancing factor isoform 4 (NKEF) | IN | IN | IN | 6 | 48 | 4.6E− 113 | 86.61 | gi|50751518 | 22.1/23.77 |
| 1753 | Cadherin 4, type 1, R-cadherin (retinal) (CADH4) | IN | AB | AB | 1 | 5 | 0.000240 | 2.68 | gi|52138677 | 100.8/26.5 |
| 1427 | Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6 (SERPINB6) | REP | − 1.4 | − 2.7 | 4 | 19 | 5.2E− 33 | 19.89 | gi|57530448 | 42.9/40.60 |
| 917 | Ferritin, heavy polypeptide 1 (FTH1) | AB | 1.2 | REP | 3 | 30 | 3.8E− 38 | 19.77 | gi|45384172 | 21.1/21.64 |
| 1612 | Myosin regulatory light chain 9 (MYL9) | IN | 1.9 | 1.3 | 1 | 7 | 5.6E− 08 | 5.76 | gi|45384118 | 19.8/21.52 |
| 968 | Myosin regulatory light chain, isoform L20-B (MYLL20B) | − 2.3 | 1 | REP | 2 | 15 | 2.7E− 12 | 8.38 | gi|45384410 | 19.8/20.42 |
| 704 | Transglutaminase 4 (prostate) (TGM4) | 8 | − 1.3 | − 1.1 | 7 | 15 | 3.8E− 84 | 56.85 | gi|57530757 | 78.8/30.85 |
| 111 | Transglutaminase 4 (prostate) (TGM4) | − 2.7 | − 2.5 | − 1.6 | 9 | 24 | 8.2E− 121 | 65.80 | gi|57530757 | 78.8/89.70 |
| 1765 | PREDICTED: hypothetical protein (HP1) | IN | AB | AB | 2 | 19 | 5.0E− 17 | 8.34 | gi|50731161 | 34.5/35.40 |
| 585 | PREDICTED: hypothetical protein (HP2) | − 2.3 | 1 | − 1.2 | 3 | 15 | 6.3E− 29 | 19.97 | gi|50745642 | 34.8/34.74 |
| 1655 | PREDICTED: hypothetical protein (HP3) | REP | REP | REP | 1 | 5 | 9.7E− 05 | 1.12 | gi|50761148 | 38.4/22.29 |
| 347 | PREDICTED: hypothetical protein, partial (HP4) | IN | 1 | 1.8 | 8 | 16 | 3.8E− 54 | 44.03 | gi|118093732 | 51.7/55.78 |
| 1610 | PREDICTED: hypothetical protein (HP5) | 2.2 | 2.8 | 3.7 | 1 | 3 | 1.2E− 07 | 6.58 | gi|118086389 | 32.8/20.78 |
IN = induced, detected only in infected group, REP = repressed, detected only in the control group, AB = absent in both groups, dpi = days post-infection.
Protein abbreviations are in parentheses.
Protein coverage = (total amino acids in detected peptides / total amino acids in peptides detectable by mass spectrometer) × 100 (see Materials and methods section for details).
Protein score is the sum of Xcorr values obtained from Bioworks analysis.
Fig. 4Venn diagram summarizing the spots that were significantly differentially expressed in the spleen tissues of MDV-infected chickens according to their corresponding time of sampling. These identities include both quantitatively and qualitatively differentially expressed spots. The identities of spots which were commonly expressed were placed in overlapping areas accordingly. Corresponding spot numbers are in parentheses. Refer to Table 1 for the respective protein names.
Fig. 5Gene Ontology analysis of significantly changed proteins according to their biological process. This classification was produced based on the analysis using GOSlimViewer tool at Agbase database (http://www.agbase.msstate.edu/) as described in the Materials and methods section.
Fig. 6MDV genome load in infected spleens. Chickens were infected with the RB1B strain of MDV and sampled at 7, 14 and 21 days post-infection. Meq copy numbers in 100 ng of spleen DNA were quantitated using real-time PCR. At least three spleen samples were analyzed in duplicate at each sampling time point. The error bars represent standard error of the mean.